Other paradigms: Randomized discontinuation trial design

Cancer Journal

Volumn 15, Issue 5, 2009, Pages 431-434

  Stadler, Walter ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MC2115 ^*  (United States)

Author keywords

Clinical trial design; Phase II; Randomization

Indexed keywords

CANCER GROWTH; CANCER RESEARCH; CANCER THERAPY; HUMAN; METHODOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZATION; REVIEW; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 70350163202     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181bd0431     Document Type: Review

References (17)

1. Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer. 1976;38:388-394.
2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
3. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol. 2003;21:2574-2582.
4. Karrison TG, Maitland ML, Stadler WM, et al. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007;99:1455-1461.
5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
7. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-296.
8. Schwartz LH, Mazumdar M, Wang L, et al. Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. Cancer. 2003;98:1611-1619.
9. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-2096.
10. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002;20:4478-4484.
11. Stadler WM. The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents. Mol Cancer Ther. 2007;6:1180-1185.
12. Freidlin B, Simon R. Evaluation of randomized discontinuation design. J Clin Oncol. 2005;23:5094-5098.
13. Kopec JA, Abrahamowicz M, Esdaile JM. Randomized discontinuation trials: utility and efficiency. J Clin Epidemiol. 1993;46:959-971.
14. Galsky MD, Zaks T, Hassani H, et al. Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest New Drugs. In press.
15. Ratain MJ, Eisen T, Stadler WM, et al. Phase II Placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512.
16. Stadler WM, Rosner G, Small E, et al. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma -CALGB 69901. J Clin Oncol. 2005;23:3726-3732.
17. Booth B, Glassman R, Ma P. Oncology's trials. Nat Rev Drug Discov. 2003;2:609-610.